Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

Intellia Therapeutics (NASDAQ:NTLA) shares plummeted 50% on Monday after the company announced a temporary halt to patient dosing and screening in its Phase 3 trials of nex-z, citing a serious ...

CRISPR technology may soon lead to major stock growth in genomics. CRISPR therapies target diseases with genetic editing either inside or outside the body. Beam, CRISPR Therapeutics, Caribou, and ...

Ermias Kebreab, left, and Matthias Hess, right, with the College of Agricultural and Environmental Sciences, will work with UC collaborators to cut methane emissions from cow guts using the ...